Literature DB >> 16971529

Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.

Jenny E Westin1, Hanna S Lindgren, Jonathan Gardi, Jens Randel Nyengaard, Patrik Brundin, Paul Mohapel, M Angela Cenci.   

Abstract

3,4-Dihydroxyphenyl-L-alanine (L-DOPA)-induced dyskinesia is associated with molecular and synaptic plasticity in the basal ganglia, but the occurrence of structural remodeling through cell genesis has not been explored. In this study, rats with 6-hydroxydopamine lesions received injections of the thymidine analog 5-bromo-2'-deoxyuridine (BrdU) concomitantly with L-DOPA for 2 weeks. A large number of BrdU-positive cells were found in the striatum and its output structures (globus pallidus, entopeduncular nucleus, and substantia nigra pars reticulata) in L-DOPA-treated rats that had developed dyskinesia. The vast majority (60-80%) of the newborn cells stained positively for endothelial markers. This endothelial proliferation was associated with an upregulation of immature endothelial markers (nestin) and a downregulation of endothelial barrier antigen on blood vessel walls. In addition, dyskinetic rats exhibited a significant increase in total blood vessel length and a visible extravasation of serum albumin in the two structures in which endothelial proliferation was most pronounced (substantia nigra pars reticulata and entopeduncular nucleus). The present study provides the first evidence of angiogenesis and blood-brain barrier dysfunction in an experimental model of L-DOPA-induced dyskinesia. These microvascular changes are likely to affect the kinetics of L-DOPA entry into the brain, favoring the occurrence of motor complications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16971529      PMCID: PMC6674611          DOI: 10.1523/JNEUROSCI.0944-06.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  37 in total

1.  Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.

Authors:  K Elisabet Ohlin; Irene Sebastianutto; Chris E Adkins; Cornelia Lundblad; Paul R Lockman; M Angela Cenci
Journal:  Neuroimage       Date:  2012-03-03       Impact factor: 6.556

2.  Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease.

Authors:  Lissa S Brod; Jason L Aldred; John G Nutt
Journal:  Mov Disord       Date:  2012-04-16       Impact factor: 10.338

Review 3.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

4.  Hyper-oligodendrogenesis at the vascular niche and reduced blood-brain barrier integrity in the prefrontal cortex during protracted abstinence.

Authors:  Sucharita S Somkuwar; McKenzie J Fannon; Tran Bao Nguyen; Chitra D Mandyam
Journal:  Neuroscience       Date:  2017-09-01       Impact factor: 3.590

5.  Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy.

Authors:  Brinda Desai Bradaric; Aditiben Patel; Julie A Schneider; Paul M Carvey; Bill Hendey
Journal:  J Neural Transm (Vienna)       Date:  2011-07-12       Impact factor: 3.575

6.  Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia.

Authors:  Vincent A Jourdain; Chris C Tang; Florian Holtbernd; Christian Dresel; Yoon Young Choi; Yilong Ma; Vijay Dhawan; David Eidelberg
Journal:  JCI Insight       Date:  2016-09-22

7.  Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.

Authors:  Matteo Marti; Donata Rodi; Qin Li; Remo Guerrini; Stefania Fasano; Ilaria Morella; Alessandro Tozzi; Riccardo Brambilla; Paolo Calabresi; Michele Simonato; Erwan Bezard; Michele Morari
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

Review 8.  The blood-brain barrier in neurodegenerative disease: a rhetorical perspective.

Authors:  Paul M Carvey; Bill Hendey; Angela J Monahan
Journal:  J Neurochem       Date:  2009-07-31       Impact factor: 5.372

9.  Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease.

Authors:  Shigeki Hirano; Kotaro Asanuma; Yilong Ma; Chengke Tang; Andrew Feigin; Vijay Dhawan; Maren Carbon; David Eidelberg
Journal:  J Neurosci       Date:  2008-04-16       Impact factor: 6.167

10.  Phenotype analysis and quantification of proliferating cells in the cortical gray matter of the adult rat.

Authors:  Tetsuji Mori; Taketoshi Wakabayashi; Yasuharu Takamori; Kotaro Kitaya; Hisao Yamada
Journal:  Acta Histochem Cytochem       Date:  2009-02-17       Impact factor: 1.938

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.